Shamburg News · 8-K filed Oct 27, 2026, 6:06 AM EDT

Aclaris Reports Positive Phase 1b ATI-052 Results in Atopic Dermatitis and Asthma; Cash Estimate $204.6M

ACRS · Aclaris Therapeutics, Inc.

  • Other event
  • Financial statements
  • Other
  • Materiality: high

Aclaris Therapeutics announced primary analysis results from Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma, reporting a 45% placebo-adjusted mean EASI improvement at day 57 in atopic dermatitis and a 59% mean FeNO reduction at day 15 in asthma. The company estimated unaudited cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026, and said it intends to prioritize ATI-052 development in eosinophilic esophagitis with a Phase 2b trial planned for early 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 8.01, 9.01, accession 0001104659-26-118952.

Written from the filing by Shamburg Markets. Figures are as reported by the company.